Etiology and Management of Seborrheic Dermatitis

Seborrheic dermatitis (SD) is a common dermatological disorder that varies greatly in severity between individuals and with time. The etiology of this disease is poorly understood. Early investigators focused on the role of Malassezia (previously Pityrosporum) yeasts in the development of SD. Some researchers have hypothesized that there is an immunological component to SD and that this disease is caused by an altered immune response to Malassezia yeasts. However, other researchers view this condition as the result of hyperproliferation. Both antifungal and anti-inflammatory preparations have been used to treat SD effectively and safely. The wide range of antifungal formulations available (creams, shampoos, oral drugs) provides safe, effective and flexible treatment options for SD.

[1]  J. Ring,et al.  Effects ofPityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFNγ) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis , 1996, Archives of Dermatological Research.

[2]  Aditya K. Gupta,et al.  Role of Antifungal Agents in the Treatment of Seborrheic Dermatitis , 2004, American journal of clinical dermatology.

[3]  B. Dréno,et al.  Lithium gluconate 8% vs. ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study , 2003, The British journal of dermatology.

[4]  S. Soon,et al.  Tacrolimus 0·1% ointment for seborrhoeic dermatitis: an open‐label pilot study , 2003, The British journal of dermatology.

[5]  O. Chosidow,et al.  Randomized, Open-Labeled, Non-Inferiority Study between Ciclopiroxolamine 1% Cream and Ketoconazole 2% Foaming Gel in Mild to Moderate Facial Seborrheic Dermatitis , 2003, Dermatology.

[6]  G. Varigos,et al.  Ciclopiroxolamine Cream for Treating Seborrheic Dermatitis: A Double-Blind Parallel Group Comparison , 2002, Infection.

[7]  B. Dréno,et al.  Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. , 2002, European journal of dermatology : EJD.

[8]  C. Crutchfield.  Pimecrolimus: a new treatment for seborrheic dermatitis. , 2002, Cutis.

[9]  T. Boekhout,et al.  Fast, Noninvasive Method for Molecular Detection and Differentiation of Malassezia Yeast Species on Human Skin and Application of the Method to Dandruff Microbiology , 2002, Journal of Clinical Microbiology.

[10]  G. Piérard,et al.  A Double-Blind Placebo-Controlled Study of Ketoconazole + Desonide Gel Combination in the Treatment of Facial Seborrheic Dermatitis , 2002, Dermatology.

[11]  M. Ghannoum,et al.  Voriconazole -- better chances for patients with invasive mycoses. , 2002, European journal of medical research.

[12]  K. Goode,et al.  A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral ® ) for the treatment of dandruff/seborrhoeic dermatitis , 2002, The Journal of dermatological treatment.

[13]  M. Barbareschi,et al.  Itraconazole: new horizons , 2002 .

[14]  P. Elsner,et al.  [Clinical effectiveness and tolerance of climbazole containing dandruff shampoo in patients with seborrheic scalp eczema]. , 2001, Praxis.

[15]  B. Perfetto,et al.  Malassezia furfur invasiveness in a keratinocyte cell line (HaCat): effects on cytoskeleton and on adhesion molecule and cytokine expression , 2001, Archives of Dermatological Research.

[16]  J. Faergemann.  Treatment of seborrhoeic dermatitis with oral terbinafine? , 2001, The Lancet.

[17]  R. Summerbell,et al.  Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. , 2001, Medical mycology.

[18]  A. Hasegawa,et al.  The effects of Malassezia yeasts on cytokine production by human keratinocytes. , 2001, The Journal of investigative dermatology.

[19]  G. Quadri,et al.  Evaluation of the efficacy and tolerability of oral terbinafine (Daskil®) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator‐blinded, placebo‐controlled trial , 2001, The British journal of dermatology.

[20]  I. Bergbrant,et al.  Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry , 2001, The British journal of dermatology.

[21]  D. Parsad,et al.  Topical Metronidazole in Seborrheic Dermatitis – A Double-Blind Study , 2001, Dermatology.

[22]  G. Midgley.  The lipophilic yeasts: state of the art and prospects. , 2000, Medical mycology.

[23]  H. Hönigsmann,et al.  Narrow‐band ultraviolet B (TL‐01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis , 2000, The British journal of dermatology.

[24]  Á. Vera Casaño,et al.  Malassezia globosa as the causative agent of pityriasis versicolor , 2000, The British journal of dermatology.

[25]  H. Trau,et al.  Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole , 2000, International journal of dermatology.

[26]  J. Faergemann.  Management of Seborrheic Dermatitis and Pityriasis Versicolor , 2000, American journal of clinical dermatology.

[27]  D. Bucks,et al.  Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against Malassezia furfur species and seborrheic dermatitis , 2000 .

[28]  J. Guillot,et al.  Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. , 2000, Medical mycology.

[29]  J. Faergemann,et al.  Cell‐mediated immunity to Malassezia furfur in patients with seborrhoeic dermatitis and pityriasis versicolor , 1999, Clinical and experimental dermatology.

[30]  Parry,et al.  Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast , 1998, The British journal of dermatology.

[31]  R. A. Schwartz,et al.  Tinea versicolor: an update. , 1998, Cutis.

[32]  Isaac Shiri,et al.  Treatment of seborrheic dermatitis of the scalp and dandruff with a shampoo containing 1% bifonazole (Agispor shampoo) , 1998 .

[33]  H. Korting,et al.  The hydroxypyridones: a class of antimycotics of its own , 1997, Mycoses.

[34]  I. Orengo,et al.  Anti‐inflammatory activity of antifungal preparations , 1997, International journal of dermatology.

[35]  R. Hay,et al.  Dandruff and seborrhoeic dermatitis: causes and management , 1997, Clinical and experimental dermatology.

[36]  H. Nakagawa,et al.  Tacrolimus Has Antifungal Activities against Malassezia furfur Isolated from Healthy Adults and Patients with Atopic Dermatitis , 1996 .

[37]  Y. Loria,et al.  Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: new treatment options , 1996, The British journal of dermatology.

[38]  S. Oliveri,et al.  Phospholipase activity in Malassezia furfur pathogenic strains , 1996, Mycoses.

[39]  K. Zug,et al.  Dermatologic diagnosis and treatment of itchy red eyelids. , 1996, Survey of ophthalmology.

[40]  J. Ring,et al.  Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFNγ) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis , 1996, Archives of Dermatological Research.

[41]  K. Smith,et al.  Cutaneous findings in HIV-1-positive patients: a 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). , 1994, Journal of the American Academy of Dermatology.

[42]  I. Bergbrant,et al.  Adherence of Malassezia furfur to human stratum corneum cells in vitro: a study of healthy individuals and patients with seborrhoeic dermatitis , 1994, Mycoses.

[43]  A. Katsambas,et al.  FACIAL SEBORRHEIC DERMATITIS TREATED WITH FLUCONAZOLE 2% SHAMPOO , 1994, International journal of dermatology.

[44]  E. Anaissie,et al.  Malassezia and Trichosporon: two emerging pathogenic basidiomycetous yeast-like fungi. , 1994, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[45]  B. Elewski.  Mechanisms of action of systemic antifungal agents. , 1993, Journal of the American Academy of Dermatology.

[46]  J. Ortonne,et al.  Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. , 1992, Dermatology.

[47]  T. Hoehler,et al.  Ciclopirox olamine: a hydroxypyridone antifungal agent. , 1991, Clinics in dermatology.

[48]  H. Hänel,et al.  [Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect]. , 1991, Mycoses.

[49]  I. Bergbrant,et al.  Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. , 1989, Acta dermato-venereologica.

[50]  J. Faergemann.  Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a double-blind study. , 1988, Cutis.

[51]  R. Hay,et al.  Serological responses to Pityrosporum (Malassezia) in seborrhœic dermatitis demonstrated by ELISA and western blotting , 1988 .

[52]  J. Faergemann.  SEBORRHOEIC DERMATITIS AND Pityrosporum orbiculare: TREATMENT OF SEBORRHOEIC DERMATITIS OF THE SCALP WITH MICONAZOLE‐HYDROCORTISONE, MICONAZOLE, AND HYDROCORTISONE , 1987 .

[53]  J. Faergemann.  Pharmacology and Treatment Seborrhoeic dermatitis and Pityrosporumorbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole‐hydrocortisone (Daktacort), miconazole and hydrocortisone , 1986, The British journal of dermatology.

[54]  A. Scheynius,et al.  An immunologic and cultural study of Pityrosporum folliculitis. , 1986, Journal of the American Academy of Dermatology.

[55]  R. Marks,et al.  The effects of a shampoo containing zinc pyrithione on the control of dandruff , 1985, The British journal of dermatology.

[56]  C. Farthing,et al.  Skin disease in homosexual patients with Acquired Immune Deficiency Syndrome (AIDS) and lesser forms of human T cell Leukaemia Virus (HTLV III) disease , 1985, Clinical and experimental dermatology.

[57]  P. Farr,et al.  The response of seborrhoeic dermatitis to ketoconazole , 1984, The British journal of dermatology.

[58]  S. Shuster.  THE AETIOLOGY OF DANDRUFF AND THE MODE OF ACTION OF THERAPEUTIC AGENTS , 1984, The British journal of dermatology.

[59]  R. L. Binder,et al.  Seborrheic dermatitis in neuroleptic-induced parkinsonism. , 1983, Archives of dermatology.

[60]  M. Rapaport.  A Randomized, Controlled Clinical Trial of Four Anti-Dandruff Shampoos , 1981, The Journal of international medical research.

[61]  J. Faergemann,et al.  Tinea versicolor with regard to seborrheic dermatitis. An epidemiological investigation. , 1979, Archives of dermatology.

[62]  Rt M. KLICMaN,et al.  The Nature of Dandruff , 1976 .

[63]  J. Leyden,et al.  Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. , 1975, The Journal of investigative dermatology.

[64]  N. Orentreich,et al.  Comparative study of two antidandruff preparations. , 1969, Journal of pharmaceutical sciences.